Danaher Corporation's Stock Analysis

Danaher Approves New Share Repurchase Program for 35 Million Shares

Danaher Corporation's Board of Directors has amended the Company’s By-laws to update the procedures for shareholders to propose business at meetings, including director nominations. These changes also include routine updates and revisions to the By-laws.

On the same date, the Board approved a new share repurchase program allowing the Company to buy back up to 35 million shares of its common stock. This program can be executed through various methods such as open market purchases and has no expiration date, continuing until further notice. The management will determine the timing and amount of repurchases based on market conditions.

Sep 10, 2025 07:24:19

Danaher General Counsel to Transition Role Before Retirement

Brian W. Ellis, Senior Vice President and General Counsel of Danaher Corporation, has announced his intention to step down from his role as General Counsel effective August 25, 2025. He will continue to serve as Senior Vice President until his retirement on February 28, 2026.

This transition in leadership may impact the company's legal and operational strategies during the upcoming months as Danaher prepares for Ellis's eventual retirement. Investors may want to monitor any changes in the company's governance structure or legal affairs as a result of this announcement.

Jul 31, 2025 16:31:51

Danaher Announces CFO Transition and Compensation Changes

Matthew M. McGrew, the current Chief Financial Officer of Danaher Corporation, will step down from his role effective February 28, 2026, transitioning to continue as an Executive Vice President. Matthew E. Gugino, currently the Group CFO for the Life Sciences Innovations Group, will succeed him. Gugino's compensation will increase to an annual base salary of $825,000, with a target bonus percentage of 115% and a target equity compensation value of $4,200,000 for 2026, reflecting his new role. McGrew's base salary will also be adjusted to $700,000 with a target bonus of 125% upon his transition.

The company has established agreements to protect proprietary interests and ensure non-competition from Gugino during and after his employment. McGrew has been with Danaher for over 20 years and played a significant role in the company's growth, including major acquisitions and navigating challenges during the pandemic. The transition is expected to occur smoothly, with McGrew remaining to support the company during this period.

Jul 24, 2025 16:50:27

Danaher Reports Second Quarter 2025 Financial Results

Danaher Corporation announced its financial results for the quarter ending June 27, 2025, reporting net earnings of $555 million, equivalent to $0.77 per diluted share. Revenue increased by 3.5% year-over-year to $5.9 billion, with non-GAAP core revenue growth of 1.5%. Operating cash flow was reported at $1.3 billion, and non-GAAP free cash flow reached $1.1 billion. The company's CEO highlighted the robust growth in the Bioprocessing sector and effective cost management as key contributors to exceeding quarterly expectations.

For the upcoming quarters, Danaher anticipates low-single-digit growth in non-GAAP core revenue for the third quarter and maintains a full-year growth expectation of approximately 3%. The company has also raised its guidance for adjusted diluted net earnings per share to a range of $7.70 to $7.80, up from the previous estimate of $7.60 to $7.75. An investor conference call was scheduled to discuss these results and future financial guidance.

Jul 21, 2025 17:47:55

Danaher Reports Q1 2025 Results with Revenue Decline

Danaher Corporation announced its financial results for the first quarter of 2025, reporting net earnings of $1.0 billion, or $1.32 per diluted share. Revenue decreased by 1.0% to $5.7 billion, while non-GAAP core revenue remained flat compared to the previous year. The company generated operating cash flow of $1.3 billion and non-GAAP free cash flow of $1.1 billion. The CEO highlighted strong performance in bioprocessing and respiratory demand in the diagnostics sector as key contributors to the results.

Looking ahead, Danaher expects non-GAAP core revenue to grow in the low-single digits year-over-year for the second quarter of 2025, maintaining an annual growth expectation of approximately 3%. The company is initiating guidance for adjusted diluted net earnings per common share in the range of $7.60 to $7.75 for the full year. Danaher will discuss these results and its financial outlook during an investor conference call.

Apr 22, 2025 06:08:20

Danaher Reports $3.9 Billion Net Earnings for 2024

Danaher Corporation reported net earnings of $1.1 billion for the fourth quarter of 2024, translating to $1.49 per diluted share. The company's revenues increased by 2% year-over-year to $6.5 billion, with operating cash flow at $2 billion and non-GAAP free cash flow of $1.5 billion. For the full year, net earnings reached $3.9 billion, with revenues remaining flat at $23.9 billion. Non-GAAP adjusted diluted net earnings per common share were $7.48 for the year.

However, the full year results showed a decline in non-GAAP core revenue by 1.5%, reflecting challenges in maintaining revenue growth. The company anticipates a low-single-digit decline in non-GAAP core revenue for the first quarter of 2025, indicating potential ongoing difficulties in revenue generation. Additionally, the overall performance was impacted by impairment charges and the termination of a commercial agreement, which could affect future profitability.

Jan 28, 2025 17:45:21

Danaher Reports Low-Single Digit Revenue Growth for Q4 2024

Danaher Corporation announced that its estimated revenues for the fourth quarter of 2024 are expected to rise in the low-single digit percent range compared to the previous year. The company also noted that its estimated non-GAAP core revenue is anticipated to remain flat year-over-year, which is better than the prior guidance of a low-single digit percent decline. This performance will be discussed in detail by CEO Rainer M. Blair at the upcoming J.P. Morgan Healthcare Conference.

On the downside, while revenue growth is projected, the core revenue's stagnation raises concerns about underlying business momentum. The company faces challenges such as fluctuating demand for COVID-19 related products and broader economic uncertainties that could impact future performance. Additionally, factors like competition and the ability to innovate and market new products will be crucial for maintaining growth in a competitive landscape.

Jan 13, 2025 16:22:11

Danaher Reports Strong Q3 2024 Earnings and Growth

Danaher Corporation announced its third quarter 2024 results, highlighting a net earnings increase to $818 million and a revenue growth of 3% year-over-year, reaching $5.8 billion. The company noted significant cash flow generation, with $1.5 billion from operating cash flow and $1.2 billion in free cash flow. The bioprocessing sector showed positive momentum, and the CEO expressed optimism about the company's strong market position and commitment to improving human health through innovation.

However, looking ahead, Danaher anticipates a decline in non-GAAP core revenue for both the fourth quarter and the full year, projecting a low-single-digit decrease year-over-year. This outlook raises concerns about future sales performance, particularly in its Biotechnology and Life Sciences segments, which experienced declines. Despite the strong quarterly performance, the anticipated revenue drop may impact investor sentiment moving forward.

Oct 21, 2024 17:47:57

Danaher Reports Mixed Results for Second Quarter 2024

Danaher Corporation reported net earnings of $907 million for Q2 2024, exceeding expectations, but revenues fell 3% year-over-year to $5.7 billion. The company highlighted strong performance in its bioprocessing and molecular testing sectors. While cash flow remained robust, Danaher anticipates low-single digit declines in core revenue for both Q3 and the full year 2024, indicating potential challenges ahead.

Jul 22, 2024 17:47:44

Danaher Corporation Reports Strong Q1 2024 Results

Danaher Corporation announced solid Q1 2024 results with $1.1 billion net earnings, $5.8 billion revenues, and $1.7 billion operating cash flow. The company's CEO highlighted better-than-expected performance and market share gains in bioprocessing and molecular diagnostics businesses. Despite a decrease in revenues, Danaher remains optimistic about its long-term performance and human health impact. The forecast for Q2 2024 suggests a mid-single-digit revenue decline, with a low-single-digit decrease expected for the full year. Danaher's focus on innovation and science to enhance health outcomes is emphasized.

Apr 22, 2024 18:00:43